Skip to main content
SpringerLink
Log in

Genetically Engineered Human Immunodeficiency Virus Type 1 (HIV-1) Vaccines

  • Chapter
Modern Vaccinology

  • 110 Accesses

Abstract

The human immunodeficiency virus type 1 (HIV-1) is the etiological agent of acquired immunodeficiency syndrome (AIDS) and related disorders (Barre-Sinoussi et al., 1983; Gallo et al., 1984; Popovic et al., 1984). The World Health Organization has recently estimated that 8–10 million people worldwide are infected with HIV-1 and that this number will rise to 40 million by the year 2000 (Ksparza et al., 1991). Global projections of cumulative total cases of AIDS patients by this time are in the neighbourhood of 15–18 million. The development of an effective, long-lasting vaccine against HIV-1 represents, therefore, a formidable scientific challenge for the international AIDS research community in its efforts to control the spread of this epidemic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ada, G. (1992). The design and testing of HIV prophylactic vaccines. AIDS Res. Hum. Retroviruses 8: 758–763.

    CAS  Google Scholar 

  • Adams, S.E., Dawson, K.M., Gull, K., Kingsman, S.M., and Kingsman, A.J. (1987). The expression of the hybrid HIV: Ty virus-like particles in yeast. Nature 329: 68–70.

    PubMed  CAS  Google Scholar 

  • Agy, M.B., Frumkin, L.R., Corey, L., Coombs, R.W., Wolinsky, S.M., Koehler, J., Morton, W.R., and Katze, M.G. (1992). Infection of Macaca nemestraina by human immunodeficiency virus type-1. Science 257: 103–106.

    PubMed  CAS  Google Scholar 

  • Akerblom, L., Nara, P., Dunlop, N., and Morein, B. (1991). Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response. AIDS Res. Hum. Retroviruses 7: 621–627.

    PubMed  CAS  Google Scholar 

  • Aldovini, A., and Young, R.A. (1991). Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351: 479–482.

    PubMed  CAS  Google Scholar 

  • Aldovini, A. and Young, R.A. (1990). Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J. Virol. 64: 1920–1926.

    PubMed  CAS  Google Scholar 

  • Allan, J.S., Coligan, J.E., Barin, F., McLane, M.F., Sodroski, J.G., Rosen, C.A., Haseltine, W.A., Lee, T.H., and Essex, M. (1985). Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228: 1091–1093.

    PubMed  CAS  Google Scholar 

  • Alter, H.J., Eichberg, J.W., Masur, H., Saxinger, W.C., Gallo, R., Macher, A.M., Lane, H.C., and Fauci, A.S. (1984). Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science 226: 549–552.

    PubMed  CAS  Google Scholar 

  • Anderson, K.P., Lucas, C., Hanson, C.V., Londe, H.F., Izu, A., Gregory, T., Ammann, A., Berman, P.W., and Eichberg, J.W. (1989). Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1. J. Infect. Dis. 160: 960–969.

    CAS  Google Scholar 

  • Archibald, D.W., Hebert, C.A., Sun, D., and Tacket, C.O. (1990). Salivary antibodies to human immunodeficiency virus type 1 in a phase 1 AIDS vaccine trial. J. Acquir. Immune Defic. Syndr. 3: 954–958.

    PubMed  CAS  Google Scholar 

  • Arthur, L.O., Pyle, S.W., Nara, P.L., Bess, J.W. Jr., Gonda, M.A., Kelliher, J.C., Gilden, R.V., Robey, W.G., Bolognesi, D.P., Gallo, R.C., and Fischinger, P.J. (1987). Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc. Natl. Acad. Sci. 84: 8583–8587.

    PubMed  CAS  Google Scholar 

  • Arthur, L.O., Bess, J.W. Jr., Waters, D.J., Pyle, S.W., Kelliher, J.C., Nara, P.L., Krohn, K., Robey, W.G., Langlois, A.J., Gallo, R.C., and Fischinger, P.J. (1989). Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J. Virol. 63: 5046–5053.

    PubMed  CAS  Google Scholar 

  • Barber, J.R., Jolly, D.J., St. Louis, D., and Warner, J.F. (1991). Utilization of retroviral vectors for the potential treatment of AIDS, pp. 329–355. In W.C. Koff, F. Wong-Staal, and R.C. Kennedy (ed.), AIDS Research Reviews. Marcel Dekker, Inc., New York.

    Google Scholar 

  • Barin, F., McLane, M.F., Allan, J.S., Lee, T.H., Groopman, J.E., and Essex, M. (1985). Vims envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science 228: 1094–1096.

    PubMed  CAS  Google Scholar 

  • Barr, P.J., Steimer, K.S., Sabin, E.A., Parkes, D., and George-Nscimento, C., Stephans, J.C., Powers, M.A., Gyenes, A., Van Nest, G.A., Miller, E.T., Higgins, K.W., and Luciw, P.A. (1987). Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae. Vaccine 5: 90–101.

    PubMed  CAS  Google Scholar 

  • Barre-Sinoussi, F., Chermann, J., Rey, F., Nugeyre, M., Chamaret, S., Gmest, J., and Dauguet, C., Axler-Blin, C., Vezinet-Bmn, F., Rouzioux, C., Rozenbaum, W., and Montagnier, L. (1983). Isolation of a T-lymphotropic retrovirus from a patient at riks for acquired immune deficiency syndrome (AIDS). Science 220: 868–871.

    PubMed  CAS  Google Scholar 

  • Barrett, N., Mitterer, A., Mundt, W., Eibl, J., Eibl, M., Gallo, R.C., Moss, B., and Dorner, F. (1989). Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS Res. Hum. Retroviruses 5: 159–171.

    PubMed  CAS  Google Scholar 

  • Belshe, R.B., Clements, M.L., Dolin, R., Corey, L., Graham, B., Bolognesi, D., Stablein, D., Eibl, M., Fast, P., and the NIAID AIDS Vaccine Clinical Trials Network. (1992). Safety and immunogenicity of fully glycosylated rgp160 IIIB vaccine in low risk volunteers. VIII International Conference on AIDS, Amsterdam (Abstract PoA 2432).

    Google Scholar 

  • Berman, P.W., Groopman, J.E., Gregory, T., Clapham, P.R., Weiss, R.A., Ferriani, R., Riddle, L., Shimasaki, C., Lucas, C. Lasky, L.A., and Eichberg, J.W. (1988). Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc. Natl. Acad. Sci. 85: 5200–5204.

    PubMed  CAS  Google Scholar 

  • Berman, P.W., Riddle, L., Nakamura, G., Haffar, O.K., Nunes, W.M., Skehel, P., Byrn, R., Groopman, J., Matthews, T., and Gregory, T. (1989). Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160. J. Virol. 63: 3489–3498.

    PubMed  CAS  Google Scholar 

  • Berman, P.W., Gregory, T.J., Lavon, R., Nakamura, G.R., Champe, M.A., Porter, J.P., Wurm, F.M., Hershberg, R.D., Cobb, E.K., and Eichberg, J.W. (1990). Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345: 622–625.

    PubMed  CAS  Google Scholar 

  • Berman, P.W., Matthews, T.J., Riddle, L., Champe, M., Hobbs, M.R., Nakamura, G.R., Mercer, J., Eastman, DJ., Lucas, C., Langlois, A.J., Wurm, F.M., and Gregory, T.J. (1992). Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol 66: 4464–4469.

    PubMed  CAS  Google Scholar 

  • Biselli, R., Loomis, L.D., Del Bono, V., Burke, D.S., Redfield, R.R., and Birx, D.L. (1992). Vaccine-therapy with gp160: effect on human anti-gp120 antibody spectrotype. VIII International Conference on AIDS, Amsterdam (Abstract MoA 0011).

    Google Scholar 

  • Bolognesi, D.P. (1991). Vaccines against acquired immunodeficiency syndrome, pp. 389–405. In R.C. Gallo and G. Jay (ed.), The Human Retroviruses. Academic Press, Inc., San Diego, CA.

    Google Scholar 

  • Bomford, R., Stapleton, M., Winsor, S., McKnight, A., and Andronova, T. (1992). The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res. Hum. Retroviruses 8: 1765–1771.

    PubMed  CAS  Google Scholar 

  • Borisova, G.P., Berzins, I., Pushko, P.M., Pumpen, P., Gren, E.J., Tsibinogin, V.V., Loseva, V., Ose, V., Ulrich, R., Siakkou, H., and Rosenthal, H.A. (1989). Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface. FEBS Lett. 259: 121–124.

    PubMed  CAS  Google Scholar 

  • Boursnell, M.E.G., (1992). Avipoxvirus vectors, pp. 269–283. In M.M. Binns and G.L. Smith (ed.), Recombinant Poxviruses. CRC Press, Boca Raton, F1.

    Google Scholar 

  • Bratt, G., Eriksson, L., Sandstrom, E. Gilljam, G., Hinkula, J., and Wahren, B. (1992). A study of a gp160 vaccine in healthy HIV-carriers with and wihtout zidovudine. VIII International Conference on AIDS, Amsterdam (Abstract PoB 3036).

    Google Scholar 

  • Buchbinder, A., Karwoska, S., Gorny, M.K., Burda, ST., and Zolla-Pazner, S. (1992). Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res. Hum. Retroviruses 8: 425–427.

    PubMed  CAS  Google Scholar 

  • Burke, K.L., Dunn, G., Ferguson, M., Minor, P.D., and Almond, J.W. (1988). Antigen chimaeras of poliovirus as potential new vaccines. Nature 332: 81–82.

    PubMed  CAS  Google Scholar 

  • Calmette, A., Guerin, C., and Weill-Halle, B. (1924). Essais d’imnnmisation contre l’infection tuberculeuse. Bull. Acad. Natn. Med. (Paris) 91: 787–796.

    Google Scholar 

  • Carlson, J.R., McGraw, T.P., Keddie, E., Yee, J.L., Rosenthal, A., Langlois, A.J., Dickover, R., Donovan, R., Luciw, P.A., Jennings, M.B., and Gardner, M.B. (1990). Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res. Hum. Retroviruses 6: 1239–1246.

    PubMed  CAS  Google Scholar 

  • Castro, B.A., Cheng-Mayer, C., Evans, L.A., and Levy, J.A. (1988). HIV heterogeneity and viral pathogenesis. AIDS 2(suppl 1): S17–S27.

    PubMed  Google Scholar 

  • Chakrabarti, S., Robert-Guroff, M., Wong-Staal, F., Gallo, R.C., and Moss, B. (1986). Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature 320: 535–537.

    PubMed  CAS  Google Scholar 

  • Chanda, P.K., Natuk, R.J., Mason, B.B., Bhat, B.M., Greenberg, L., Dheer, S.K., Molnar-Kimber, K.L., Mizutani, S., Lubeck, M.D., Davis, A.R., and Hung, P.P. (1990). High level expression of the envelope glycoproteins of the human immunodeficiency virus type 1 in presence of rev gene using helper-independent adenovirus type 7 recombinants. Virology 175: 535–547.

    PubMed  CAS  Google Scholar 

  • Chapman, B.S., Thayer, R.M., Vincent, K.A., and Haigwood, N.L. (1991). Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acis Res. 19: 3979–3986.

    CAS  Google Scholar 

  • Cheng-Mayer, C., Homsy, J., Evans, L., and Levy, J. (1988). Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc. Natl. Acad. Sci. 85: 2815–2819.

    PubMed  CAS  Google Scholar 

  • Chernoff, D., Kahn, J., Sinangil, F., Murcar, N., Wynne, D., Coleman, R., Haigwood, N., Steimer, K., and Dekker, C. (1992). Phase I dose escalation MTP-PE study of an HIV-1 gp120 vaccine in seronegative adults. VIII International Conference on AIDS, Amsterdam (Abstract MoB 0025).

    Google Scholar 

  • Clements, M.L., Belshe, R., Duliege, A.M., Schwartz, D., Gorse, G., Izu, A., Ammann, A., and the NIAID-sponsored AIDS Vaccine Clinical Trials Network. (1992). Safety and immunogenicity of IIIB rgp120/HIV-1 vaccine in seronegative volunteers. VIII International Conference on AIDS, Amsterdam (Abstract Mob 0026).

    Google Scholar 

  • Clements, J.E. and Wong-Staal, F. (1992). Molecular biology of lentiviruses. Semin. Virol. 3: 137–146.

    CAS  Google Scholar 

  • Clerici, M., Tacket, C.O., Via, C.S., Lucey, D.R., Muluk, S.C., Zajac, R.A., Boswell, R.N., Berzofsky, J.A., and Shearer, G.M. (1991). Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur. J. Immunol. 21: 1345–1349.

    PubMed  CAS  Google Scholar 

  • Connor, R. and Ho, D. (1992). Pathogenesis of human immunodeficiency virus. Semin. Virol. 3: 213–224

    CAS  Google Scholar 

  • Cooney, E.L., Collier, A.C., Greenberg, P.D., Coombs Robert W., Zarling, J., Arditti, D.E., Hoffman, M.C., Hu, S-L., and Corey, L. (1991). Safety of an immunological response to a recombiant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337: 567–572.

    PubMed  CAS  Google Scholar 

  • Cordonnier, A., Riviere, Y., Montagnier, L., and Emerman, M. (1989). Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding. J. Virol. 63: 4464–4468.

    PubMed  CAS  Google Scholar 

  • Corey, L. (1992). Phase I trials of subunit gp160 vaccines: A current summary. J. Cell. Biochem. Supplement 16E: 9 (Abstract Q022).

    Google Scholar 

  • Cox, W.I., Tartaglia, J., and Paoletti, E. (1992). Poxvirus recombinants as live vaccines, pp. 123–162. In M.M. Binns and G.L. Smith (ed.), Recombinant Poxviruses. CRC Press, Boca Raton, F1.

    Google Scholar 

  • Dalgleish, A.G., Beverley, P.C.L., Clapham, P.R., Crawford, D.H., Greaves, M.F., and Weiss, R.A. (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retroviruses. Nature 312: 763–767.

    PubMed  CAS  Google Scholar 

  • Dallo, S. Maa, J.S., Rodriguez, J.R., Rodriguez, D., and Esteban, M. (1989). Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein. Virology 173: 323–329.

    PubMed  CAS  Google Scholar 

  • Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K., and Desrosiers, R.C. (1992). Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938–1941.

    PubMed  CAS  Google Scholar 

  • Desrosiers, R.C., Wyand, M.S., Kodama, T., Ringler, D.J., Arthur, L.O., Sehgal, P.K., Letvin, N.L., King, N.W., and Daniel, M.D. (1989). Vaccine protection against simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. 86: 6353–6357.

    PubMed  CAS  Google Scholar 

  • Desrosiers, R.C. (1992). HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res. Hum. Retroviruses 8: 411–421.

    PubMed  CAS  Google Scholar 

  • Devash, Y., Calvelli, T.A., Wood, D.G., Reagan, K.J., and Rubinstein, A. (1990). Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affmity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc. Natl. Acad. Sci. 87: 3445–3449.

    PubMed  CAS  Google Scholar 

  • Dewar, R.L., Nataranjan, V., Vasudevachari, M.B., and Salzman, N.P. (1989). Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus. J. Virol. 63: 129–136.

    PubMed  CAS  Google Scholar 

  • DiMarzo-Veronese, F., De Vico, A.L., Copeland, T.D., Oroszlan, S., Gallo, R.C., and Sarngadharan, M.G. (1985). Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 229: 1402–1405.

    Google Scholar 

  • Dolin, R., Graham, B.S., Greenberg, S.B., Tacket, C.O., Belshe, R.B., Midthun, K., Clements, M.L., Gorse, G.J., Horgan, B.W., Atmar, R.L., Karzon, D.T., Bonnez, W., Fernie, B.F., Montefiori, D.C., Stablein, D.M., Smith, G.E., Koff, W.C., and the NIAID AIDS Vaccine Clinical Trials Network. (1991). The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann. Intern. Med. 114: 119–127.

    PubMed  CAS  Google Scholar 

  • Dolin, R., Corey, L., Graham, B., Wright, P., McElrath, J., Keefer, M., Matthews, T., Stablein, D., Dekker, C., and the AIDS Vaccine Clinical Trials Network. (1992). Safety and immunogenicity of an HIV vaccine candidate, env 2–3, in combination with MTP-PE/MF59. VIII International Conference on AIDS, Amsterdam (Abstract PoA 2226).

    Google Scholar 

  • Dorner, F., Barrett, N., and Moss, B. (1990). Large-scale production, purification, and immunologic analysis of a vaccinia recombinant derived HIV-1 gp160, pp. 219–240. In S.D. Putney and D.P. Bolognesi (ed.), AIDS Vaccine Research and Clinical Trials. Marcel Dekker, Inc., New York.

    Google Scholar 

  • Dowbenko, D., Nakamura, G., Fennie, C., Shimasaki, C., Riddle, L., Harris, R., Gregory, T., and Lasky, L. (1988). Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies. J. Virol. 62: 4703–4711.

    PubMed  CAS  Google Scholar 

  • Earl, P.L., Robert-Guroff, M., Matthews, T.J., Krohn, K., London, W.T., and Moss, B. (1989). Isolate-and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques. AIDS Res. Hum. Retrovirises 5: 23–32.

    CAS  Google Scholar 

  • Emini, E.A., Scheleif, W.A., Nunberg, J.H., Conley, A.J., Eda, Y., Tokiyoshi, S., Putney, S.D., Matsushita, S., Cobb, K.E., Jett, C.M., Eichberg, J.W., and Murthy, K.K. (1992). Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355: 728–730.

    PubMed  CAS  Google Scholar 

  • Esparza, J., Osmanov, S., Kallings, L.O., and Wigzell, H. (1991). Planning for HIV vaccine trials: the World Health Organization Perspective. AIDS 5(suppl 2): S159–S163.

    PubMed  Google Scholar 

  • Evans, D.J., McKeating, J., Meredith, J.M., Burke, K.L., Katrak, K., John, A., Ferguson, M., Minor, P.D., Weiss, R.A., and Almond, J.W. (1989). An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339: 385–388.

    PubMed  CAS  Google Scholar 

  • Fast, P.E., and Walker, M.C. (1993). Human trials of experimental AIDS vaccines. In press. In AIDS 92/93. Current Science Press, Philadelphia, Pennsylvania.

    Google Scholar 

  • Feinberg, M.B., and Greene, W.C. (1992). Molecular insights into human immunodeficiency virus type 1 pathogenesis. Curr. Opin. Immunol. 4: 466–474.

    PubMed  CAS  Google Scholar 

  • Fisher, A.G., Ratner, L., Mitsuya, H., Marselle, L.M., Harper, M.E., Broder, S., Gallo, R.C., and Wong-Staal, F. (1986). Infectious mutants of HTLV-III with changes in the 3′ region and markedly reduced cytopathic effects. Science 233: 655–659.

    PubMed  CAS  Google Scholar 

  • Fisher, A.G., Ensoli, B., Looney David, Rose, A., Gallo, R.C., Saag, M.S., Shaw, G.M., Hahn, B.H., and Wong-Staal, F. (1988). Biologically diverse molecular variants within a single HIV-1 isolate. Nature 334: 444–447.

    PubMed  CAS  Google Scholar 

  • Freed, E.O., Myers, D.J., and Risser, R. (1989). Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J. Virol. 63: 4670–4675.

    PubMed  CAS  Google Scholar 

  • Frey, S.E., Gorse, G.J., Newman, F.K., Belshe, R.B., and the NIAID AIDS Vaccine Clinical Trials Network. (1991). Anti-gp160 enzyme linked immunosorbent assay antibody responses to a combination of human immunodeficiency virus vaccine regimen. Clin. Res. 39: 727A.

    Google Scholar 

  • Fultz, P.N., McClure, H.M., Swenson, R.B., McGrath, C.R., Brodie, A., Getchell, J.P., Jensen, F.C., Anderson, D.C., Broderson, J.R., and Francis, D.P. (1986). Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J. Virol. 58: 116–124.

    PubMed  CAS  Google Scholar 

  • Fultz, P.N. (1991). Human immunodeficiency virus infection of chimpanzees: an animal model for asymptomatic HIV carriers and vaccine efficacy, pp. 207–218. In W.C. Koff, F. Wong-Staal, and R.C. Kennedy (ed.), AIDS Research Reviews. Marcel Dekker, Inc., New York.

    Google Scholar 

  • Gallo, R.C., Salahuddin, S.Z., Popovic, M., Shearer, G.M., Kaplan, M., Haynes, B.F., Palker, T.J., Redfield, R., Oleske, J., Safai, B., White, G., Foster, P., and Markham, P.D. (1984). Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500–503.

    PubMed  CAS  Google Scholar 

  • Gardner, M. (1991a). SIV vaccines: current status. Vaccine 9: 787–791.

    PubMed  CAS  Google Scholar 

  • Gardner, M.B. (1991b). Simian and feline immunodeficiency vieuses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents. Antiviral Res. 15: 267–286.

    PubMed  CAS  Google Scholar 

  • Gardner, M.B., and Hu, S. (1991). SIV vaccines, (1991)-a year in reveiw. AIDS 5(suppl 2): S115–S127.

    PubMed  Google Scholar 

  • Gheysen, D., Jacobs, E., de Foresta, F., Thiriart, C., Francotte, M., Thines, D., and De Wilde, M. (1986). Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59: 103–112.

    Google Scholar 

  • Giavedoni, L.D., Jones, L., Gardner, M.B., Gibson, H.L., Ng, C.T.L., Barr, P.J., and Yilma, T. (1992). Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc. Natl. Acad. Sci. 89: 3409–3413.

    PubMed  CAS  Google Scholar 

  • Girard, M., Keiny, M-P., Pinter, A., Barre-Sinoussi, F., Nara, P. Kolbe, H., Kusumi, K., Chaput, A., Reinhart, T., Muchmore, E., Ronco, J., Kaczorek, M., Gomard, E., Gluckman, J-C., and Fultz, P.N. (1991). Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. 88: 542–546.

    PubMed  CAS  Google Scholar 

  • Gorelick, R.J., Nigida, S.M. Jr., Bess, J.W. Jr., Arthur, L.O., Henderson, L.E., and Rein, A. (1990). Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J. Virol. 64: 3207–3211.

    PubMed  CAS  Google Scholar 

  • Gorse, G.J., Belshe, R.B., Newman, F.K., Frey, S.E., and the NIAID AIDS Vaccine Clinical Trials Network. (1992a). Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160. Vaccine 10: 383–388.

    PubMed  CAS  Google Scholar 

  • Gorse, G.J., Frey, S.E., Newman, F.K., Belshe, R.B., and AIDS Vaccine Clinical Trials Network. (1992b). Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. J. Clin. Microbiol. 30: 2606–2612.

    PubMed  CAS  Google Scholar 

  • Gorse, G., Belshe, R., and the AIDS Vaccine Clinical Trials Network. (1992c). Lymphocyte proliferation following vaccination with fully glycosylated gp160. VIII International Conference on AIDS, Amsterdam (Abstract PoB 3038).

    Google Scholar 

  • Gottlinger, H.G., Sodroski, J.G., and Haseltine, W.A. (1989). Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad Sci. 86: 5781–5785.

    PubMed  CAS  Google Scholar 

  • Goudsmit, J. (1988). Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts. AIDS 2: 541–545.

    Google Scholar 

  • Graham, B.S., Belshe, R.B., Clements, M.L., Dolin, R., Corey, L., Wright, P.F., Gorse, G.J., Midthun, K., Keefer, M.C., Roberts, N.J. Jr., Schwartz, D.H., Agosti, J.M., Fernie, B.F., Stablein, D.M., Montefiori, D.C., Lambert, J.S., Hu, S-L., Esterlitz, J.R., Lawrence, D.N., Koff, W.C., and the NIAID AIDS Vaccine Clinical Trials Netwrok. (1992a). Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The J. Infect Dis. 166: 244–252.

    CAS  Google Scholar 

  • Graham, B.S., Belshe, R., Clements, M.L., and et al. (1992b). Determinants of antibody (AB) response in volunteers primed with vac-env and boosted with rgp160. VIII International Conference on AIDS, Amsterdam (Abstract MoA 0013).

    Google Scholar 

  • Graham, B.S., Matthews, T.J., Belshe, R.B., Clements, M.L., Dolin, R., Wright, P.W., Gorse, G.J., Schwartz, D.H., Keefer, M.C., Bolognesi, D.P., Corey, L., Stablein, D.M., Esterlitz, J.R., Hu, S-L., Smith, G.E., Fast, P.E., Koff, W.C., and the AIDS Vaccine Clinical Trials Network. (1993). Augmentation of HIV-1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160. J. Infect. Dis. 167: 533–537.

    PubMed  CAS  Google Scholar 

  • Graham, F.L., and Prevec, L. (1992). Adenovirus-based expression vectors and recombinant vaccines, pp. 363–390. In R. Ellis (ed.), Vaccines: New Approaches to Immnunological Problems. Butterworth-Heinemann, Stoneham, MA.

    Google Scholar 

  • Griffiths, J.C., Berrie, E.L., Holdsworth, L.N., Moore, J.P., Harris, S.J., Senior, J.M., Kingsman, S.M., Kingsman, A.J., and Adams, S.E. (1991). Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty virus-like particles in a clinically relevant adjuvant. J. Virol. 65: 450–456.

    PubMed  CAS  Google Scholar 

  • Guo, H.G., de Marzo Veronese, F., Tschachler, E., Pal, R., Kalyanaraman, V.S., Gallo, R.C., and Reitz, M.S. Jr. (1990). Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage. Virology 174: 217–224.

    PubMed  CAS  Google Scholar 

  • Habeshaw, J., Hounsell, E., and Dalgleish, A. (1992). Does the HIV envelope induce a chronic GVH-like disease?. Immunol. Today 13: 207–210.

    PubMed  CAS  Google Scholar 

  • Haffar, O., Garrigues, J., Travis, B., Moran, P., Zarling, J., and Hu, S-L. (1990). Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 64: 2653–2659.

    PubMed  CAS  Google Scholar 

  • Haffar, O.K., Smithgall, M.D., Moran, P.A>, Travis, B.M., Zarling, J.M., Hu, S-L. (1991). HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles. Virology 183: 487–495.

    PubMed  CAS  Google Scholar 

  • Hahn, B.H., Shaw, G.M., Taylor, M.E., Redfield, R.R., Markham, P.D., Salahuddin, S., Wong-Staal, F., Gallo, R.C., Parks, E.S., and Parks, W.P. (1986). Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science 232: 1548–1553.

    PubMed  CAS  Google Scholar 

  • Hahn, B.H., and Shaw, G.M. (1990). Genetic variability in human immunodeficiency viruses, pp. 121–135. In S.D. Putney and D.P. Bolognesi (ed.), AIDS Vaccine Research and Clinical Trials. Marcel Dekker, Inc., New York.

    Google Scholar 

  • Haigwood, N.L., Sinister, J.R., Moore, G.K., Lee, H., Skiles, P.V., Higgins, K.W., Barr, P.J., George-Nascimento, C., and Steimer, K.S. (1990). Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses 6: 855–869.

    PubMed  CAS  Google Scholar 

  • Haigwood, N.L., Nara, P.L., Brooks, E., Van Nest, G.A., Ott, G., Higgins, K.W., Dunlop, N., Scandella, C.J., Eichberg, J.W., and Steimer, K.S. (1992). Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 66: 172–182.

    PubMed  CAS  Google Scholar 

  • Hammond, S.A., Obah, E., Stanhope, P., Monell, C.R., Strand, M., Robbins, F.M., Bias, W.B., Karr, R.W., Koenig, S., and Siliciano, R.F. (1991). Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. J. Immunol. 146: 1470–1477.

    PubMed  CAS  Google Scholar 

  • Hammond, S.A., Bollinger, R.C., Stanhope, P.E., Quinn, T.C., Schwartz, D., Clements, M.L., Siliciano, R.F. (1992). Comparative clonal analysis of human immunodeficiency virus type 1 (HlV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candiate HIV-1 vaccines. J. Exp. Med. 176: 1531–1542.

    PubMed  CAS  Google Scholar 

  • Haseltine, W.A. (1991). Human immunodeficiency virus (HIV) gene expression and function, pp. 69–106. In R.C. Gallo and G. Jay (ed.), The Human Retroviruses. Academic Press, Inc., San Diego, CA.

    Google Scholar 

  • Haubrich, R.H., Takeda, A. Koff, W., Smith, G., and Ennis, F.A. (1992). Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection medicated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine. J. Infect. Dis. 165: 545–548.

    PubMed  CAS  Google Scholar 

  • Haynes, J.R., Cao, S.X., Rovinski, B., Sia, C., James, O., Dekaban, G.A., and Klein, M.H. (1991). Production of immunogenic HIV-1 virus-like particles in stably engineered monkey cell lines. AIDS Res. Hum. Retroviruses 7: 17–27.

    PubMed  CAS  Google Scholar 

  • Ho, D.D., McKeating, J.A., Li, X.L., Moudgil, T., Daar, E.S., Sun, N-C., and Robinson, J.E. (1991). Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 nuetralization identified by a human monoclonal antibody. J. Virol. 65: 489–493.

    PubMed  CAS  Google Scholar 

  • Homsy, J., Meyer, M., and Levy, J.A. (1990). Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J. Virol. 64: 1437–1440.

    PubMed  CAS  Google Scholar 

  • Hu, S.-L., Kosowski, S.G., and Dalrymple, J.M. (1986). Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature 320: 537–540.

    PubMed  CAS  Google Scholar 

  • Hu, S-L., Kosowski, S.G., and Schaaf, K.F. (1987a). Expression of envelope glycoproteins of human immunodeficiency virus by an insect virus vector. J. Virol. 61: 3617–3620.

    PubMed  CAS  Google Scholar 

  • Hu, S-L., Fultz, P.N., McClure, H.M., Eichberg, J.W., Thomas, E.K., Zarling, J., Singhal, M.C., Kosowski, S.G., Swenson, R.B., Anderson, D.C., and Todaro, G. (1987b). Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature 328: 721–723.

    PubMed  CAS  Google Scholar 

  • Hu, S-L., Zarling, J.M., Chinn, J., Travis, B.M., Moran, P.A., Sias, J., Kuller, L., Morton, W.R., Heidecker, G., Benveniste, R.E., (1989). Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus. Proc. Natl. Acad. Sci. 86: 7213–7217.

    PubMed  CAS  Google Scholar 

  • Hu, S-L., Travis, B.M., Garrigues, J., Zarling, J.M., Sridhar, P., Dykers, T., Eichberg, J.W., and Alpers, C. (1990). Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus. Virology 179: 321–329.

    PubMed  CAS  Google Scholar 

  • Hu, S-L., Klaniecki, J., Dykers, T., Sridhar, P., and Travis, B.M. (1991). Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia viurs expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160. AIDS Res. Hum. Retroviruses 7: 615–620.

    PubMed  CAS  Google Scholar 

  • Hu, S-L., Abrams, K., Barber, G.N., Moran, P., Zarling, J.M.L., Langlois, A.J., Kuller, L., Morton, W.R., and Benveniste, R.E. (1992). Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255: 456–459.

    PubMed  CAS  Google Scholar 

  • Hunt, L.A., Brown, D.W., Robinson, H.L., Naeve, C.W., and Webster, R.G. (1988). Retrovirus-expressed hemagglutinin protects against lethal influenza virus infections. J. Virol. 62: 3014–3019.

    PubMed  CAS  Google Scholar 

  • Husson, R.N., James, B.E., and Young, R.A. (1990). Gene replacement and expression of foreign DNA in mycobacteria. J. Bacteriol. 172: 519–524.

    PubMed  CAS  Google Scholar 

  • Isaacson, R.E. (1992). The rationale for rDNA vaccines, pp. 1–17. In R.E. Isaacson (ed.), Recombinant DNA Vaccines. Marcel Dekker, Inc., New York.

    Google Scholar 

  • Ivey-Hoyle, M., and Rosenberg, M. (1990). Rev-dependent expression of human immunodeficiency virus type 1 gp160 in Drosophila melanogaster cells. Mol. Cell. Biol. 10: 6152–6159.

    PubMed  CAS  Google Scholar 

  • Jacobs, W.R. Jr., Tuckman, M., and Bloom, B.R. (1987). Introduction of foreign DNA into mycobacteria using a shuttle plasmid. Nature 327: 532–535.

    PubMed  CAS  Google Scholar 

  • Jarrett, O., Yamamoto, J.K., and Neil, J.C. (1990). Feline immunodeficiency virus as a model for AIDS vaccination. AIDS 4: S163–S165.

    PubMed  Google Scholar 

  • Javaherian, K., Langlois, A.J., LaRosa, G.J., Profy, A.T., Bolognesi, D.P., Herlihy, W.C., Putney, S.D., and Matthews, T.J. (1990). Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250: 1590–1593.

    PubMed  CAS  Google Scholar 

  • Jolly, D.J., and Warner, J.F. (1990). Retroviral vectors as vaccines and immunothepeutics. Semin. Immunol. 2: 329–339.

    PubMed  CAS  Google Scholar 

  • Karacostas, V., Nagashima, K., Gonda, M.A., and Moss, B. (1989). Human immunodeficiency virus-like particles produced by a vaccinia virus experssion vector. Proc. Natl. Acad. Sci. 86: 8964–8967.

    PubMed  CAS  Google Scholar 

  • Karzon, D.T., Bolognesi, D.P., and Koff, W.C. (1992). Development of a vaccine for the prevention of AIDS a critical appraisal. Vaccine 10: 1039–1052.

    PubMed  CAS  Google Scholar 

  • Keefer, M.C., Bonnez, W., Roberts, N.J. Jr., Dolin, R., and Reichman, R.C. (1991). Human immunodeficiency virus (HIV-1) gp160 specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J. Infect. Dis. 163: 448–453.

    PubMed  CAS  Google Scholar 

  • Keefer, M., Belshe, R., Clements, M., Graham, B., Corey, L., Bolognesi, D., Stablein, D., Koff, W., Montefiori, D., Smith, G., Dolin, R., and the NIAID AIDS Vaccine Clinical Traials Network. (1992). Safety and immunogenicity of a baculovirus-derived HIV-1 IIIB recombinant gp160 vaccine. VIII International Conference on AIDS, Amsterdam (Abstract PoA 2228).

    Google Scholar 

  • Kieny, M.P., Rautmann, G., Schmitt, D., Dott, K., Wain-Hobson, S., Alizon, M., Girard, M., Chamaret, S., Laurent, A., Montaggnier, L., and Lecocq, J-P. (1986). AIDS virus env protein expressed from a recombinant vaccinia virus. Biotechnology 4: 790–795.

    CAS  Google Scholar 

  • Kieny, M.P., Lathe, R., Riviere, Y., Dott, K., Schmitt, D., Girard, M., Montagnier, L., and Lecocq, J-P. (1988). Improved antigenicity of the HIV env protein by cleavage site removal. Protein Eng. 2: 219–225.

    PubMed  CAS  Google Scholar 

  • Kitchen, L.W., Barin, F., Sullivan, J.L., McLane, M.F., Brettler, D.B., Levine, P.H., and Essex, M. (1984). Aetiology of AIDS-antibodies to human T-cell leukaemia virus (type III) in haemophiliacs. Nature 312: 367–369.

    PubMed  CAS  Google Scholar 

  • Klaniecki, J., Dykers, T., Travis, B., Schmitt, R., Wain, M., Watson, A., Sridhar, P., McClure, J. Morein, B., Ulrich, J.T., Hu, S-L., and Lewis, J. (1991). Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus. AIDS Res. Hum. Retroviruses 7: 791–798.

    PubMed  CAS  Google Scholar 

  • Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard, D., Hercend, T., Gluckman, J-C., and Montagnier, L. (1984). T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312: 767–768.

    PubMed  CAS  Google Scholar 

  • Koff, W.C., and Hoth, D.F. (1988). Development and testing of AIDS vaccines. Science 241: 426–432.

    PubMed  CAS  Google Scholar 

  • Korber, B., Wolinsky, S., Haynes, B., Kunstman, K., Levy, R., Furtado, M., Otto, P., and Myers, G. (1992). HIV-1 Intrapatient sequence diversity in the immunogenic V3 region. AIDS Res. Hum. Retroviruses 8: 1461–1465.

    PubMed  CAS  Google Scholar 

  • Kowalski, M., Potz, J., Basiripour, L., Dorfman, T., Goh, W.C., Terwilliger, E., Dayton, A., Rosen, C., Haseltine, W., and Sodroski, J. (1987). Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237: 1351–1355.

    PubMed  CAS  Google Scholar 

  • Krausslich, H.G., Ochsenbauer, C., Traenckner, A.M., Mergener, K., Facke, M., Gelderblom, H.R., and Bosch, V. (1993). Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology 192: 605–617.

    PubMed  CAS  Google Scholar 

  • Krohn, K., Robey, W.G., Putney, S., Arthur, L., Nara, P., Fischinger, P., Gallo, R.C., Wong-Staal, F., and Ranki, A. (1987). Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-linfected men. Proc. Natl. Acad. Sci. 84: 4994–4998.

    PubMed  CAS  Google Scholar 

  • Kundu, S.K., Katzenstein, D., Moses, L.E., and Merigan, T.C. (1992). Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc. Natl. Acad Sci. 89: 11204–11208.

    PubMed  CAS  Google Scholar 

  • Kurstak, E., Kurstak, C., Hossain, A. and Al Tuwaijri A. (1993). AIDS-Vaccines to human immunodeficiency virus. A difficult Challenge. pp. 59–74. In: Control of Virus Diseases. E. Kurstak ed., Sec. Edn., Marcel Dekker, Inc., New York, Basel

    Google Scholar 

  • La Rosa, G.J., Davide, J.P., Weinhold, K., Waterbury, J.A., Profy, A.T., Lewis, J.A., Langlois, A.J., Dreesman, G.R., Boswell, R.N., Shadduck, P., Holley, L.H., Karplus, M., Bolognesi, D.P., Matthews, T.J., Emini, E.A., and Putney, S.D. (1990). Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249: 932–935.

    Google Scholar 

  • Lasky, L.A., Groopman, J.E., Fennie, C.W., Benz, P.M., Capon, D.J., Dowbenko, D.J., Nakamura, G.R., Nunes, W.M., Renz, M.E., and Berman, P.W. (1986). Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 233: 209–212.

    PubMed  CAS  Google Scholar 

  • Lasky, L.A., Nakamura, G. Smith, D.H., Fennie, C. Shimasaki, C., Patzer, E. Berman, P., Gregory, T., and Capon, D.J. (1987). Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50: 975–985.

    PubMed  CAS  Google Scholar 

  • Lasky, L.A. (1989). Current status of the development of an AIDS vaccine. Crit. Rev. Immunol. 9: 153–172.

    PubMed  CAS  Google Scholar 

  • Letvin, N.L. (1992). Animal models for the study of human immunodeficiency virus infections. Curr. Opin. Immunol. 4: 481–485.

    PubMed  CAS  Google Scholar 

  • Lever, A., Gottlinger, H., Haseltine, W., and Sodroski, J. (1989). Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J. Virol. 63: 4085–4087.

    PubMed  CAS  Google Scholar 

  • Li, J., Lord, C.I., Haseltine, W., Letvin, N.L., and Sodroski, J. (1992). Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. Acquir. Immune. Defic. Syndr. 5: 639–646.

    PubMed  CAS  Google Scholar 

  • Lifson, J.D., Feinberg, M.B., Reyes, G.R., Rabin, L., Banapour, B., Chakrabarti, S., Moss, B., Wong-Staal, F., Steimer, K.S., and Engleman, E.G. (1986). Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature 323: 725–728.

    PubMed  CAS  Google Scholar 

  • Ljunggren, K., Biberfeld, G., Jondal, M., and Fenyo, E.M. (1989). Antibody-dependent cellular cytotoxicity detects type-and strain-specific antigens among human immunodeficinecy virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates. J. Virol. 63: 3376–3381.

    PubMed  CAS  Google Scholar 

  • Lyerly, H.K., Matthews, T.J., Langlois, A.J., Bolognesi, D.P., and Weinhold, K.J. (1987a). Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc. Natl. Acad. Sci. 84: 4601–4605.

    PubMed  CAS  Google Scholar 

  • Lyerly, H.K., Reed, D.L., Matthews, T.J., Langlois, A.J., Ahearne, P.A., Petteway, S.R. Jr., and Weinhold, K.J. (1987b). Anti-gp120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res. Hum. Retroviruses 3: 409–422.

    PubMed  CAS  Google Scholar 

  • Lyerly, H.K., Tyler, D.S., Nastala, C.L., and Weinhold, K.J. (1990). Anti-HIV-1 ADCC, pp. 157–177. In S.D. Putney and D.P. Bolognesi (ed.), AIDS Vaccine Research and Clinical Trials. Marcel Dekker, Inc., New York.

    Google Scholar 

  • Mackett, M. (1992). Vaccinia virus as a cloning and elivery system for vaccines, pp. 223–264. In R.E. Isaacson (ed.), Recombinant DNA Vaccines. Marcel Dekker, Inc., New York.

    Google Scholar 

  • Mahr, A., and Payne, L.G. (1992). Vaccinia recombinants as vaccine vectors. Immunobiology 184: 126–146.

    PubMed  CAS  Google Scholar 

  • Mann, D.L., Gartner, S., Le Sane, F., Buchow, H., and Popovic, M. (1990). HIV-1 transmission and function of virus-infected monocytes/macrophages. J. Immunol. 144: 2152–2158.

    PubMed  CAS  Google Scholar 

  • Mannhalter, J.W., Pum, M., Wolf, H.M., Kupcu, Z., Barrett, N., Dorner, F., Eder, G., and Eibl, M.M. (1991a). Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory. AIDS Res. Hum. Retroviruses 7: 485–493.

    PubMed  CAS  Google Scholar 

  • Mannhalter, J.W., Barret, N., Kupcu, Z., Kistner, O., Wolf, H., Huber, K., Eder, G., Dorner, F., Gallo, R.C., Moss, B., and Eibl, M.M. (1991b). Immunological parameters associated with protection against challenge with HIV-1 in rgp160-immunized chimpanzees. VII International Conference on AIDS (Abstract TH.A.13).

    Google Scholar 

  • Marthas, M.L., Sutjipto, S., Higgins, J., Lohman, B., Torten, J., Luciw, P., Marx, P.A., and Pedersen, N.C. (1990). Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J. Virol. 64: 3694–3700.

    PubMed  CAS  Google Scholar 

  • Martin, C., Timm, J., Rauzier, J., Gomez-Lus, R., Davies, J., and Gicquel, B. (1990). Transposition of an antibiotic resistance element in mycobacteria. Nature 345: 739–743.

    PubMed  CAS  Google Scholar 

  • Matsuo, K., Yamaguchi, R., Yamazaki, A., Tasaka, H., Terasaka, K., Totsuka, M., Kobayashi, K., Yukitake, H., and Yamada, T. (1990). Establishment of a foreign antigen secretion system in mycobacteria. Infect. Immun. 58: 4049–4054.

    PubMed  CAS  Google Scholar 

  • Matthews, T.J., Langlois, A.J., Robey, W.G., Chang, N.T., Gallo, R.C., Fischinger, P.J., and Bolognesi, D.P. (1986). Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc. Natl. Acad. Sci. 83: 9709–9713.

    PubMed  CAS  Google Scholar 

  • Matthews, T.J., Lyerly, H.K., Weinhold, K.J., Langlois, A., Rusche, J., Putney, S.D., Gallo, R.C., and Bolognesi, D.P. (1987). Prospects for development of a vaccine against HTLV-III-related disorders. AIDS Res. Hum. Retroviruses 3: 197–206.

    PubMed  CAS  Google Scholar 

  • McAleer, W.J., Buynak, E.B., Maigetter, R.Z., Wampler, D.E., Miller, W.J., and Hilleman, M.R. (1984). Human hepatitis B vaccine from recombinant yeast. Nature 307: 178–180.

    PubMed  CAS  Google Scholar 

  • McCune, J.M., Rabin, L.B., Feinberg, M.B., Lieberman, M., Kosek, J.C., Reyes, G.R., and Weissman, I.L. (1988). Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53: 55–67.

    PubMed  CAS  Google Scholar 

  • McCune, J., Kaneshima, H., Krowka, J., Namikawa, R., Outzen, H., Peault, B., Rabin, L., Shih, C-C., and Yee, E. (1991). The SCID-hu mouse: a small animal model for HIV infection and pathogenesis. Annu. Rev. Immunol. 9: 399–429.

    PubMed  CAS  Google Scholar 

  • McDougal, J.S., Kennedy, M.S., Sligh, J.M., Cort, S.P., Mawle, A., and Nicholson, J.K.A. (1986). Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science 231: 382–385.

    PubMed  CAS  Google Scholar 

  • McElrath, J., Peterson, E., Dragavon, J., and et al. (1992). Combination prime-boost approach to HIV vaccination in seronegative individuals: Enhanced immunity with addtional subunit gp160 protein boosting. VIII International Conference on AIDS, Amsterdam (Abstract MoA 0027).

    Google Scholar 

  • McGhee, J.R., and Mestecky, J. (1992). The mucosal immune system in HIV infection and prospects for mucosal immunity to AIDS, pp. 289–312. In W.C. Koff, F. Wong-Staal, and R.C. Kennedy (ed.), AIDS Research Reviews. Marcel Dekker, Inc., New York.

    Google Scholar 

  • Mergener, K., Facke, M., Welker, R., Brinkmann, V., Gelderblom, H.R., and Krausslich, H-G. (1992). Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology 186: 25–39.

    PubMed  CAS  Google Scholar 

  • Meyerhans, A., Cheynier, R., Albert, J., Seth, M., Kwok, S., Sninsky, J., Morfeldt-Manson, L., Asjo, B., and Wain-Hobson, S. (1989). Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 58: 901–910.

    PubMed  CAS  Google Scholar 

  • Michel, F., Hoffenbach, A., Langlade-Demoyen, P., Guy, B., Girard, M., Lecocq, J., Wain-Hobsonn, S., Kieny, M-P., and Plata, F. (1988). HIV-specific T lymphocyte immunity in mice immunized with a recombinant vaccinia virus. Eur. J. Immunol. 18: 1917–1924.

    PubMed  CAS  Google Scholar 

  • Michel, F., Hofffenbach, A., Froussard, P., Langlade-Demoyen, P., Kaczorek, M., Kieny, M-P., and Plata, F. (1992). HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nefp27 and gagp25 proteins. AIDS Res. Hum. Retroviruses 8: 469–478.

    PubMed  CAS  Google Scholar 

  • Michel, M-L., Mancini, M., Sobczak, E., Favier, V., Guetard, D., Bahraoui, E.M., and Tiollais, P. (1988). Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles. Proc. Natl. Acad. Sci. 85: 7957–7961.

    PubMed  CAS  Google Scholar 

  • Michel, M-L., Mancini, M., Riviere, Y., Dormont, D., and Tiollais, P. (1990). T-and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/Hepatitis B surface antigen particles. J. Virol. 64: 2452–2455.

    PubMed  CAS  Google Scholar 

  • Montagnier, L., Clavel, F., Krust, B., Chamaret, S., Rey, F., Barre-Sinoussi, F., and Chermann, J.C. (1985). Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology 144: 283–289.

    PubMed  CAS  Google Scholar 

  • Montefiori, D.C., Graham, B.S., Kliks, S., Wright, P.F., and NIAID AIDS Vaccine Clinical Trials Network. (1992). Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J. Clin. Immunol. 12: 429–439.

    PubMed  CAS  Google Scholar 

  • Mosier, D.E., Gulizia, R.J., Baird, S.M., and Wilson, D.B. (1988). Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335: 256–259.

    PubMed  CAS  Google Scholar 

  • Moss, B. (1992). Vaccinia virus vectors, pp. 345–362. In R. Ellis (ed.), Vaccines: New Approaches to Immunological Problems. Butterworth-Heinemann, Stoneham, MA.

    Google Scholar 

  • Murphey-Corb, M., Martin, L.N., Davison-Fairburn, B., Montelaro, R.C., Miller, M., West, M., Olikawa, S., Baskin, G.B., Zhang, J-Y., Puteny, S.D., Allison, A.C., and Eppstein, D.A. (1989). A formalininactivated whole SIV vaccine confers protection in macaques. Science 246: 1293–1297.

    PubMed  CAS  Google Scholar 

  • Murphey-Corb, M. (1991). Whole inactivated SIV vaccines, pp. 359–368. In W.C. Koff, F. Wong-Staal, and R.C. Kennedy (ed.), AIDS Research Reviews. Marcel Dekker, Inc., New York.

    Google Scholar 

  • Myers, G., Korber, B., Berzofsky, J.A., Smith, R.F., and Pavlakis, G.N. (1992). Human Retroviruses and AIDS. Theoretical Biology and Biophysics, Group T-10, Los Alamos National Laboratory, Los Alamos, NM.

    Google Scholar 

  • Nara, P.L., Robey, W.G., Pyle, S.W., Hatch, W.C., Dunlop, N.M., Bess, J.W. Jr., Kelliher, J.C., Arthur, L.O., and Fischinger, P.J. (1988). Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J. Virol. 62: 2622–2628.

    PubMed  CAS  Google Scholar 

  • Nara, P.L., Smit, L., Dunlop, N., Hatch, W., Mergres, M., Waters, D., Kelliher, J., Gallo, R.C., Fischinger, P.J., and Goudsmit, J. (1990). Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J. Virol. 64: 3779–3791.

    PubMed  CAS  Google Scholar 

  • Natuk, R.J., Chanda, P.K., Lubeck, M.D., Davis, A.R., Wilhelm, J., Hjorth, R., Wade, M.S., Bhat, B.M., Mizzutani, S., Lee, S., Eichberg, J., Gallo, R.C., Hung, P.P., and Robert-Guroff, M. (1992). Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc. Natl. Acad. Sci. 89: 7777–7781.

    PubMed  CAS  Google Scholar 

  • Niedrig, M., Hinkula, J., Weigelt, W., L’Age-Stehr, J., Pauli, G., Rosen, J., and Wahren, B. (1989). Epitope mapping of monoclonal antibodies against human immunodeficiency virus type 1 structural proteins by using peptides. J. Virol. 63: 3525–3528.

    PubMed  CAS  Google Scholar 

  • Norley, S., and Kurth, R. (1992). Vaccination against HIV. Immunobiology 184: 193–207.

    PubMed  CAS  Google Scholar 

  • Orentas, R.J., Hildreth, J.E.K., Obah, E., Polydefkis, M., Smith, G.E., Clements, M.L., and Siliciano, R.F. (1990). Induction of CD4+ human cytolytic T-cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 248: 1234–1237.

    PubMed  CAS  Google Scholar 

  • Page, M., Mills, K.H.G., Schild, G.C., Ling, C., Patel, V., McKnight, A., Barnard, A.L., Dilger, P., and Thorpe, R. (1991). Studies on the immunogenicity of Chinese hamster ovary cell-derived recombinant gp120 (HIV-1 IIIB). Vaccine 9: 47–52.

    PubMed  CAS  Google Scholar 

  • Pedersen, N.C. (1990). Feline immunodeficiency virus infection, pp. 165–183. In H. Schellekens and M.C. Horzinek (ed.), Animal Models in AIDS. Elsevier Science Publishers B. V., Amsterdam.

    Google Scholar 

  • Picard, O., Giral, P., Defer, M.C., Fouchard, M., Morel, M., Meyohas, M.C., Lebas, J., Imbert, J.C., Frottier, J., Salaun, J.J., Lurhuma, Z., Moss, B., Gallo, R.C., and Zagury, D. (1990). AIDS vaccine therapy: phase 1 trial. Lancet 336: 179.

    PubMed  CAS  Google Scholar 

  • Picard, O., Bernard, J., Lachgar, A., Fall, L., Carlotti, M., Achour, A., Carelli, C., Salaun, J.J., Mbika, J.P., Lurhuma, Z., Desgranges, C., Boyer, V., Burny, A., Zagury, J.F., Bizzini, B., and Zagury, D. (1992a). Removal of gp160 induced bio-hazards for a safe AIDS vaccine candidate. Biomed. and Pharmacother. 46: 353–357.

    CAS  Google Scholar 

  • Picard, O., Achour, A., Bernard, J., Halbreich, A., Bizzini, B., Boyer, V., Desgranges, C., Bertho, J.M., Lachgar, A., Polliotti, B., Defer, M.C., Lanneval, K., Imbert, J.C., Frottier, J., Salaun, J.J., Burny, A., and Zagury, D. (1992b). A2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160 immunized healthy seronegative humans: evidence for persistent cell-mediated immunity. J. Acquir. Immune Defic. Syndr. 5: 539–546.

    PubMed  CAS  Google Scholar 

  • Popovic, M., Sarngadharan, M., and Read, E. (1984). Detection, isolation, and continuous production of cytopathic retrovruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224: 497–500.

    PubMed  CAS  Google Scholar 

  • Prevec, L., Christie, B.S., Laurie, K.E., Bailey, M.M., Graham, F.L., and Rosenthal, K.L. (1991). Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J. Acquir. Immune Defic. Syndr. 4: 568–576.

    PubMed  CAS  Google Scholar 

  • Profy, A.T., Salinas, P.A., Eckler, L.I., Dunlop, N.M., Nara, P.L., and Putney, S.D. (1990). Epitopes recognized by the neutralizing antiboies of an HIV-1 infected individual. J. Immunol. 144: 4641–4647.

    PubMed  CAS  Google Scholar 

  • Putney, S.D., Matthews, T.J., Robey, W.G., Lynn, D.L., Robert-Guroff, M., Mueller, W.T., Langlois, A.J., Ghrayeb, J., Petteway, S.R. Jr., Weinhold, K.J., Fischinger, P.J., Wong-Staal, F., Gallo, R.C., and Bolognesi, D.P. (1986). HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science 234: 1392–1395.

    PubMed  CAS  Google Scholar 

  • Putney, S.D., Javaherian, K., Rusche, J., Matthews, T., and Bolognesi, D.P. (1990). Features of the HIV envelope and development of a subunit vaccine, pp. 3–61. In S.D. Putney and D.P. Bolognesi (ed.), AIDS Vaccine Research and Clinical Trials. Mercel Dekker, Inc., New York.

    Google Scholar 

  • Ratner, L., VanderHeyden, N., Garcia, J., Polinsky, M., Westervelt, P., and Becich, M. (1991). Formation of noninfectious HIV-1 virus particles lacking full-length envelope protein. AIDS Res. Hum. Retroviruses 7: 287–294.

    PubMed  CAS  Google Scholar 

  • Redfield, R.R., Birx, D.L., Ketter, N., Tramont, E., Polonis, V., Davis, C., Brundage, J.F., Smith, G., Johnson, S., Fowler, A., Wierzba, T., Shafferman, A., Volvovitz, F., Oster, C., Burke, D.S., and the Military Medical Consortium for Applied Retroviral Research. (1991). A phase 1 evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in pateints with early human immunodeficiency virus infection. New Engl. J. Med. 324: 1677–1684.

    PubMed  CAS  Google Scholar 

  • Redfield, R.R., Birx, D.L., Vahey, M., Johnson, S., Loomis, L., Michael, N., Polonis, V., VanCott, T., Davis, C., Bnmdage, J., Smith, G., and Burke, D.S. and the Military Medical Consortium for Applied Retroviral Research. (1992). HIV vaccine therapy: Phase 1 safety and immunogenicity using gp160. VIII International Conference on AIDS, Amsterdam (Abstract TuB0563).

    Google Scholar 

  • Redfield, R.R., and Birx, D.L. (1992). HIV-specific vaccine therapy: concepts, status, and future directions. AIDS Res. Hum. Retroviruses 8: 1051–1058.

    PubMed  CAS  Google Scholar 

  • Reuben, J.M., Liang, L., Atmar, R.L., and Greenberg, S. (1992). B-cell activation and differentiation by HIV-1 antigens among volunteers vaccinated with VaxSyn HIV-1. J. Acquir. Immune Defic. Syndr. 5: 719–725.

    PubMed  CAS  Google Scholar 

  • Robert-Guroff, M., Brown, M., and Gallo, R.C. (1985). HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 316: 72–74.

    PubMed  CAS  Google Scholar 

  • Robey, W.G., Safai, B., Oroszlan, S., Arthur, L.O., Gonda, M.A., Gallo, R.C., and Fischinger, P.J. (1985). Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 228: 593–595.

    PubMed  CAS  Google Scholar 

  • Robinson, W.E. Jr., Kawamura, T., Lake, D., Masuho, Y., Mitchell, W.M., and Hersh, E.M. (1990). Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J. Virol. 64: 5301–5305.

    PubMed  CAS  Google Scholar 

  • Rodriguez, D., Rodriguez, J-R., Rodriguez, J.F., Trauber, D., and Esteban, M. (1989). Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc. Natl. Acad. Sci. 86: 1287–1291.

    PubMed  CAS  Google Scholar 

  • Rosenberg, Z.F., and Fauci, A.S. (1991). Immunopathologic mechanisms of human immunodeficiency virus (HIV) infection, pp. 141–161. In R.C. Gallo and G. Jay (ed.), The Human Retroviruses. Academic Press, Inc., San Diego, CA.

    Google Scholar 

  • Rossi, P., Moschese, V., Broliden, P.A., Fundaro, C., Quinti, I., Plebani, A., Giaquinto, C., Tovo, P.A., Ljunggren, K., Rosen, J., Wigzell, H., Jondal, M., and Wahren, B. (1989). Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc. Natl. Acad. Sci. 86: 8055–8058.

    PubMed  CAS  Google Scholar 

  • Rovinski, B., Haynes, J.R., Cao, S.X., James, O., Sia, C., Zolla-Pazner, S., Matthews, T.J., and Klein, M.H. (1992). Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. J. Virol. 66: 4003–4012.

    PubMed  CAS  Google Scholar 

  • Ruby, J., Brinkman, C., Jones, S., and Ramshaw, I. (1990). Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2. Immunol. Cell Biol. 68: 113–117.

    PubMed  Google Scholar 

  • Rusche, J.R., Lynn, D.L., Robert-Guroff, M., Langlois, A.J., Lyerly, H.K., Carson, H., Krohn, K., Ranki, A., Gallo, R.C., Bolognesi, D.P., Putney, S.D., and Matthews, T.J. (1987). Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc. Natl. Acad. Sci. 84: 6924–6928.

    PubMed  CAS  Google Scholar 

  • Rusche, J.R., Javaherian, K., McDanal, C., Petro, J., Lynn, D.L., Grimaila, R., Langlois, A., Gallo, R.C., Arthur, L.O., Fischinger, P.J., Bolognesi, D.P., Putney, S.D., and Matthews, T.J. (1988). Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl. Acad. Sci. 85: 3198–3202.

    PubMed  CAS  Google Scholar 

  • Saag, M.S., Hahn, B.H., Gibbons, J., Li, Y., Parks, E., Parks, W.P., and Shaw, G.M. (1988). Extensive variation of human immunodeficiency virus. Nature 334: 440–444.

    PubMed  CAS  Google Scholar 

  • Sakai, K., Dewhurst, S., Ma, X., and Volsky, D.J. (1988). Differences in cytopathogenicity and host cell range among infectious molecular clones of human immunodeficiency virus type 1 simultaneously isolated from an individual. J. Virol. 62: 4078–4085.

    PubMed  CAS  Google Scholar 

  • Sakuragi, S., Shibata, R., Mukai, R., Komatsu, T., Fukasawa, M., Sakai, H., Sakuragi, J-I., Kawamura, M., Ibuki, K., Hayami, M., and Adachi, A. (1992). Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. J. Gen. Virol. 73: 2983–2987.

    PubMed  CAS  Google Scholar 

  • Salk, J. (1987). Prospects for the control of AIDS by immunizing seropositive individuals. Nature 327: 473–476.

    PubMed  CAS  Google Scholar 

  • Sarngadharan, M.G., Popovic, M., Bruch, L., Schupbach, J., and Gallo, R.C. (1984). Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 224: 506–508.

    PubMed  CAS  Google Scholar 

  • Schlienger, K., Mancini, M., Riviere, Y., Dormont, D., Tiollais, P., and Michel, M-L. (1992). Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates. J. Virol. 66: 2570–2576.

    PubMed  CAS  Google Scholar 

  • Schultz, A.M., and Koff, W.C. (1990). Prospects for an AIDS vaccine. Immunology 2: 351–359.

    CAS  Google Scholar 

  • Shioda, T., and Shibuta, H. (1990). Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 175: 139–148.

    PubMed  CAS  Google Scholar 

  • Slade, H., Turner, J., Abrams, C., Carlo, D., and Salk, J. (1992). Immunotherpy of HIV-seropositive patients: preliminary report on a dose-ranging study. AIDS Res. Hum. Retroviruses 8: 1329–1331.

    PubMed  CAS  Google Scholar 

  • Smith, A.J., Cho, M-L, Hammarskjold, M-L., and Rekosh, D. (1990). Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacemnt vector are efficiently processed and assembled into virus-like particles. J. Virol. 64: 2743–2750.

    PubMed  CAS  Google Scholar 

  • Smith, G.L., and Moss, B. (1983). Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 25: 21–28.

    PubMed  CAS  Google Scholar 

  • Snapper, S.B., Lugosi, L., Jekkel, A., Melton, R.E., Kieser, T., Bloom, B.R., and Jacobs, W.R. Jr. (1988). Lysogeny and transformation in mycobacteria: stable expression of foreign genes. Proc. Natl. Acad. Sci. 85: 6987–6991.

    PubMed  CAS  Google Scholar 

  • Sodroski, J., Goh, W.C., Rosen, C., Campbell, K., and Haseltine, W.A. (1986). Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 322: 470–474.

    PubMed  CAS  Google Scholar 

  • Sodroski, J., Kowalski, M., and Haseltine, W. (1990). Structure and function of the HIV envelope: Implications for vaccine development, pp. 93–106. In S.D. Putney and D.P. Bolognesi (ed.), AIDS Vaccine Research and Clinical Trials. Marcel Dekker, Inc., New York.

    Google Scholar 

  • Starcich, B.R., Hahn, B.H., Shaw, G.M., McNeely, P.D., Modrow, S., Wolf, H., Parks, E.S., Parks, W.P., Josephs, S.F., Gallo, R.C., and Wong-Staal, F. (1986). Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45: 637–648.

    PubMed  CAS  Google Scholar 

  • Steimer, K.S., Scandella, C.J., Skiles, P.V., and Haigwood, N.L. (1991). Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254: 105–108.

    PubMed  CAS  Google Scholar 

  • Stein, B.S., Gowda, S.D., Lifson, J.D., Penhallow, R.C., Bensch, K.G., and Engleman, E.G. (1987). pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 49: 659–666.

    PubMed  CAS  Google Scholar 

  • Stott, E.J., Chan, W.L., Mills, K.H.G., Page, M., Taffs, F., Cranage, M., Greenaway, P., and Kitchin, P. (1990). Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet 336: 1538–1541.

    PubMed  CAS  Google Scholar 

  • Stover, C.K., de la Cruz, V.F., Fuerst, T.R., Burlein, J.E., Benson, L.A., Bennett, L.T., Bansal, G.P., Young, J.F., Lee, M.H., Hatfull, G.F., Snapper, S.B., Barletta, R.G., Jacobs, W.R. Jr., and Bloom, B.R. (1991). New use of BCG for recombinant vaccines. Nature 351: 456–460.

    PubMed  CAS  Google Scholar 

  • Sutjipto, S., Pedersen, N.C., Miller, C.J., Gardner, M.B., Hanson, C.V., Gettie, A., Jennings, M., Higgins, J., and Marx, P.A. (1990). Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J. Virol 64: 2290–2297.

    PubMed  CAS  Google Scholar 

  • Tacket, C.O., Baqar, S., Munoz, C., and Murphy, J.R. (1990). Lymphoproliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160. AIDS Res. Hum. Retroviruses 6: 535–542.

    PubMed  CAS  Google Scholar 

  • Takahashi, H., Cohen Joseph, Hosmalin, A., Cease, K.B., Houghten, R., Cornette, J.L., De Lisi, C., Moss, B., Germain, R.N., and Berzofsky, J.A. (1988). An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad Sci. 85: 3105–3109.

    PubMed  CAS  Google Scholar 

  • Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R.N., and Berzofsky, J.A. (1990). Induction of CD8+ cytotoxic T-cells by immunization with purified HIV-1 envelope protein in ISCOMS. Nature 344: 873–875.

    PubMed  CAS  Google Scholar 

  • Takeda, A., Tuazon, C.U., and Ennis, F.A. (1988). Antibody-enhanced infection by HIV-1 via Fc receptormediated entry. Science 242: 580–583.

    PubMed  CAS  Google Scholar 

  • Tartaglia, J., Perkus, M.E., Taylor, J., Norton, E.K., Audonnet, J., Cox, W.I., Davis, S.W., Van der Hoeven, J., Meignier, B., Riviere, M., Languet, B., and Paoletti, E. (1992). NYVAC: a highly attenuated strain of vaccinia virus. Virology 188: 217–232.

    PubMed  CAS  Google Scholar 

  • Tartaglia, J., Taylor, J., Cox, W.I., Perkus, M.E., Paoletti, E., Radaelli, A., DeGuili-Morghen, C., Meignier, B., Audonnet, J.C., Riviere, M., and Weinhold, K.J. (1993). Novel poxvirus strains as research tools and vaccine vectors, pp. 361–378. In W.C. Koff, R.C. Kennedy, and F. Wong-Staal (ed.), AIDS Research Reviews, Marcel Dekker, Inc., New York.

    Google Scholar 

  • Thali, M., Olshevsky, U., Furman, C., Gabuzda, D., Posner, M., and Sodroski, J. (1991). Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J. Virol. 65: 6188–6193.

    PubMed  CAS  Google Scholar 

  • Tilley, S.A., Honnen, W.J., Racho, M.E., Chou, T-C., and Pinter, A. (1992). Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res.Hum. Retroviruses 8: 461–467.

    PubMed  CAS  Google Scholar 

  • Tschachler, E., Buchow, H., Gallo, R.C., and Reitz, M.S. Jr. (1990). Functional contribution of cysteine residues to the human immunodeficiency virus type 1 envelope. J. Virol. 64: 2250–2259.

    PubMed  CAS  Google Scholar 

  • Tsoukas, C., Sampalis, J., Gold, P., O’Shaughnessy, M., Wainberg, M., Smith, G., and Volvovitz, F. (1992). Specific active immunotherapy in asymptomatic HIV disease using recombinant gp160. VIII International Conference on AIDS, Amsterdam (Abstract TuB 0560).

    Google Scholar 

  • Turner, J.L., Slade, H.B., Trauger, R.J., Ferre, F., Jensen, F.C., Carlo, D.J., and Salk, J.E. (1992). Double-blind, placebo-controlled dose ranging study of Salk immunogen in incomplete Freund’s adjuvant in asymptomatic patients with early human immunodeficiency virus infection. VIII International Conference on AIDS, Amsterdam (Abstract PoB 3043).

    Google Scholar 

  • Typer, D.S., Stanley, S.D., Zolla-Pazner, S., Gorny, M.K., Shadduck, P.P., Langlois, A.J., Matthews, T.J., Boiognesi, D.P., Palker, T.J., and Weinhold, K.J. (1990). Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J. Immunol. 145: 3276–3282.

    Google Scholar 

  • Valentine, F., Katzenstein, D., Haslett, P., Beckett, L., Borucki, M., Vasquez, M., Smriti, K., Smith, G., Korvick, J., Kagan, J., and Merigan, T. (1992). A randomized, controlled study of immunogenicity of rgp160 vaccine in HIV infected subjects. VIII International Conference on AIDS, Amsterdam (Abstract TuB 0561).

    Google Scholar 

  • Van Eendenburg, J-P., Yagello, M., Girard, M., Kieny, M-P., Lecocq, J-P., Muchmore, E., Fultz, P.N., Riviere, Y., Montagnier, R.L., and Gluckman, J-C. (1989). Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses. AIDS Res. Hum. Retroviruses 5: 41–50.

    PubMed  Google Scholar 

  • Vasudevachari, M.B., Uffelman, K.W., Kovacs, J., Yeh, C-K., Lane, H.C., and Salzman, N.P. (1992). Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160. J. Acquir. Immune Defic. Syndr. 5: 817–821.

    PubMed  CAS  Google Scholar 

  • Viscidi, R., Ellerbeck, E., Garrison, L., Midthun, K., Clements, M.L., Clayman, B., Fernie, B., Smith, G., and the NIAID AIDS Vaccine Clinical Trials Network. (1990). Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. AIDS Res. Hum. Retroviruses 6: 1251–1256.

    PubMed  CAS  Google Scholar 

  • Vzorov, A.N., Bukrinsky, M.I., Grigoriev, V.B., Tentsov, Y.Y., and Bukrinskaya, A.G. (1991). Highly immunogenic human immunodeficiency virus-like particles are produced by recombinant vaccinia virus-infected cells. AIDS Res. Hum. Retroviruses 7: 29–36.

    PubMed  CAS  Google Scholar 

  • Wagner, R., Fliessbach, H., Wanner, G., Motz, M., Niedrig, M., Deby, G., von Brunn, A., and Wolf, H. (1992). Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch. Virol. 127: 117–137.

    PubMed  CAS  Google Scholar 

  • Weber, J., Kennedy, A., Callow, D., Zigmond, A., Cheingsong-Popov, R., Martin, S., Vyakarnam, A., Gotch, F., McMichael, A., Adams, S., Blake, P., and Kingsman, A. (1992). A phase 1 study of the safety and immunogenicity of Ty.p24 VLP in healthy volunteers. VIII International Conference on AIDS, Amsterdam (Abstract PoA 2240).

    Google Scholar 

  • Weiss, R.A., Clapham. P.R., Cheingsong-Popov, R., Dalgleish, A.G., Carne, C.A., Weller, I.V.D., and Tedder, R.S. (1985). Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 316: 69–72.

    PubMed  CAS  Google Scholar 

  • Weiss, R.A., Clapham, P.R., Weber, J.N., Dalgleish, A.G., Lasky, L.A., and Berman, P.W. (1986). Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 324: 572–575.

    PubMed  CAS  Google Scholar 

  • Wells, D.E., and Compans, R.W. (1990). Expression and characterization of a functional human immunodeficiency virus envelope glycoprotein in insect cells. Virology 176: 575–586.

    PubMed  CAS  Google Scholar 

  • Wigzell, H. (1991). Prospects for an HIV-vaccine. FASEB J. 5: 2406–2411.

    PubMed  CAS  Google Scholar 

  • Willey, R.L., Bonifacino, J.S., Potts, B.J., Martin, M.A., and Klausner, R.D. (1988a). Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc. Natl. Acad. Sci. 85: 9580–9584.

    PubMed  CAS  Google Scholar 

  • Willey, R.L., Smith, D.H., Lasky, L.A., Theodore, T.S., Earl, P.L., Moss, B., Capon, D.J., and Martin, M.A. (1988b). In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62: 139–147.

    PubMed  CAS  Google Scholar 

  • Winter, N., Lagranderie, M., Rauzier, J., Timm, J., Leclerc, C., Guy, B., Kieny, M-P., Gheorghiu, M., and Gicquel, B. (1991). Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 nef protein. Gene 109: 47–54.

    PubMed  CAS  Google Scholar 

  • Wintsch, J., Chaignat, C-L., Braun, D.G., Jeannet, M., Stalder, H., Abrignani, S., Montagna, D., Clavijo, F., Moret, P., Dayer, J-M., Staehelin, T., Doe, B., Steimer, K.S., Dina, D., and Cmchaud, A. (1991). Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. The J. Infect. Dis. 163: 219–225.

    CAS  Google Scholar 

  • Zagury, D., Leonard, R., Fouchard, M., Reveil, B., Bernard, J., Ittele, D., Cattan, A., Zirimwabagabo, L., Kalumbu, M., Justin, W., Salaun, J-J., and Goussard, N.B. (1987). Immunization against AIDS in humans. Nature 326: 249–250.

    PubMed  CAS  Google Scholar 

  • Zagury, D., Bernard, J., Cheynier, R., Desportes, I., Leonard, R., Fouchard, M., Reveil, B., Ittele, D., Zirimwabagangabo, L., Kalumbu, M., Justin, W., Salaun, J-J., Goussard, B., Dechazal, L., Burny, A., Nara, P., and Gallo, R.C. (1988). A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature 332: 728–731.

    PubMed  CAS  Google Scholar 

  • Zagury, J.F., Cantalloube, H., Bernard, J., Lachgar, A., Fall, L., Achour, A., Mbika, J.P., Cosme, M.H., Pellion, F., Issing, W., Carelli, C., Bizzini, B., Threau, E., Callebaut, I., Burny, A., and Zagury, D. (1992). Critical sites: a semantic approach to protein sequences. Applications to the HIV-1 envelope molecule. Biomed & Pharmacother 46: 343–351.

    CAS  Google Scholar 

  • Zarling, J.M., Morton, W., Moran, P.A., McClure, J., Kosowski, S.G., and Hu, S-L. (1986). T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. Nature 323: 344–346.

    PubMed  CAS  Google Scholar 

  • Zarling, J.M., Eichberg, J.W., Moran, P.A., McClure, J., Sridhar, P., and Hu, S-L. (1987). Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J. Immunol. 139: 988–990.

    PubMed  CAS  Google Scholar 

  • Ziegner, U.J., Frank, I., Bernatowicz, A., Starr, S.E., and Streckert, H. (1992). Antibody-dependent cellular cytotoxicity (ADCC) is directed against immunodominant epitopes of the envelope proteins of human immunodeficiency virus 1 (HIV-1). Viral Immunol. 5: 273–281.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Connaught Centre for Biotechnology Research, Connaught Laboratories Ltd., Willowdale, Ontario, Canada

    Benjamin Rovinski & Michel Klein

Authors
  1. Benjamin Rovinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Montreal, Montreal, Quebec, Canada

    Edouard Kurstak

  2. World Health Organization, Geneva, Switzerland

    Edouard Kurstak

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rovinski, B., Klein, M. (1994). Genetically Engineered Human Immunodeficiency Virus Type 1 (HIV-1) Vaccines. In: Kurstak, E. (eds) Modern Vaccinology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1450-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-1450-7_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-1452-1

  • Online ISBN: 978-1-4899-1450-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation